Q-State Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Q-State Biosciences, Inc. - overview
Established
2014
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Q-State Biosciences, Inc. is focused on developing innovative therapies for central nervous system disorders, leveraging advanced technologies to optimize drug discovery and therapeutic solutions for complex neurological conditions. Founded in 2014 in Cambridge, US, Q-State Biosciences, Inc. specializes in therapeutic development for central nervous system disorders.
The company has successfully navigated a business strategy focused on leveraging advanced scientific methodologies. The co-founders include Adam Cohen, David Margulies, and Graham Dempsey, while Paul Medeiros currently serves as the CEO. The company raised Series A funding in November 2018, securing an undisclosed amount for further development. Q-State Biosciences has completed one total deal to date.
Q-State Biosciences develops transformative therapeutics targeting various neurological conditions, including chronic pain, seizure disorders, and genetic syndromes such as Fragile X and Dup15q Syndromes. The company employs human disease models, artificial intelligence, and advanced engineering techniques to identify therapeutic candidates. Their offerings are aimed at healthcare professionals, research institutions, and pharmaceutical companies across North America, Europe, and select markets in Asia. Q-State Biosciences follows a partnership-driven revenue model, generating income through collaborations with research institutions and pharmaceutical companies.
Revenue comes from licensing agreements that allow clients to utilize Q-State’s proprietary technologies for drug discovery, including milestone payments and royalties linked to product development and market success. Looking ahead, Q-State Biosciences plans to introduce new therapeutic products aimed at addressing specific neurological disorders, although exact release dates are not specified. The company is also targeting expansion into additional markets across Europe and Asia by 2024. The funds raised during the Series A round in November 2018 are anticipated to support these initiatives, facilitating the advancement of Q-State's drug candidates and broadening their market reach.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT
Website
www.qstatebio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.